AbbVie Inc. (ABBV)

Compare

201.50

+12.05

(+6.36%)

At close: 4:00 p.m. EDT

201.29

-0.21

(-0.10%)

After hours: 4:18 p.m. EDT

Key Events

Advanced Chart

Loading Chart for ABBV

9/21 12:03 PM

DELL

Previous Close 189.45
Open 191.62
Bid 201.72 x 900
Ask 201.39 x 800
Day's Range 188.54 - 202.35
52 Week Range 135.85 - 202.35
Volume 8,263,245
Avg. Volume 4,651,546
Market Cap (intraday) 355.917B
Beta (5Y Monthly) 0.62
PE Ratio (TTM) 67.39
EPS (TTM) 2.99
Earnings Date Oct 30, 2024
Forward Dividend & Yield 6.20 (3.27%)
Ex-Dividend Date Oct 15, 2024
1y Target Est 203.67

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

www.abbvie.com

50,000